The findings suggest that patients with certain alleles (AR (CAG)M and the heterozygous APEX1 c.444TG genotype) are linked to an increased risk of prostate cancer relapse, even when accounting for conventional clinicopathological variables. The gene discussed is APEX1; the disease is prostate carcinoma.